Vasculitis-Associated Auto-antibodies and Complement Levels in patients with COVID-19 Infection

Mobini, Maryam; Ghasemian, Roya; Larijani, Laleh Vahedi; Mataji, Maeede; Maleki, Iradj

doi:10.21203/rs.3.rs-30488/v1

Cited by 6 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, none of these patients had a history of systemic autoimmune rheumatic disease. Similarly, rheumatoid factor, ANA, and ANCA were detected in another cohort of severe and critically ill COVID-19 patients (Mobini et al, 2020). A recent report showed that 10.2% (101/987) of patients with life-threatening COVID-19 pneumonia had neutralizing IgG autoantibodies against IFN-ω and IFN-α at the onset of the critical disease.…”

Section: Antibody-mediated Pathogenesis In Covid-19 Patientsmentioning

confidence: 74%

Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?

Zhang

Zhan

et al. 2020

Sci. China Life Sci.

View full text Add to dashboard Cite

The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people and caused tremendous morbidity and mortality worldwide. Effective treatment for coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 infection is lacking, and different therapeutic strategies are under testing. Host humoral and cellular immunity to SARS-CoV-2 infection is a critical determinant for patients’ outcomes. SARS-CoV-2 infection results in seroconversion and production of anti-SARS-CoV-2 antibodies. The antibodies may suppress viral replication through neutralization but might also participate in COVID-19 pathogenesis through a process termed antibody-dependent enhancement. Rapid progress has been made in the research of antibody response and therapy in COVID-19 patients, including characterization of the clinical features of antibody responses in different populations infected by SARS-CoV-2, treatment of COVID-19 patients with convalescent plasma and intravenous immunoglobin products, isolation and characterization of a large panel of monoclonal neutralizing antibodies and early clinical testing, as well as clinical results from several COVID-19 vaccine candidates. In this review, we summarize the recent progress and discuss the implications of these findings in vaccine development.

show abstract

Section: Antibody-mediated Pathogenesis In Covid-19 Patientsmentioning

confidence: 74%

Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?

Zhang

Zhan

et al. 2020

Sci. China Life Sci.

View full text Add to dashboard Cite

show abstract

“…By December 2020, according to WHO data, more than 75 million people had been infected with COVID-19, as well as more than 1.6 million deaths from the virus worldwide [4]. The symptoms of this disease are very diverse and are seen in a wide range of different organs of the body, including fever, dry cough, dyspnea, cardiopulmonary complications, headache, lymphopenia, elevated lactate dehydrogenase, coagulation disorders, increased liver enzymes, fatigue, myalgia, secondary infections, acute kidney injury and even death in severe cases [5,6]. It should be noted that 80% of patients infected with SARS-CoV-2 have mild symptoms and a good prognosis and recover with standard treatments or without drug intervention, but about 20% of patients suffer from respiratory distress and require oxygen therapy or other inpatient interventions, including mechanical ventilation [7].…”

Section: Introductionmentioning

confidence: 99%

Patients with Covid 19 have significantly reduced CH50 activity

et al. 2021

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is a new virus that emerged in China and immediately spread around the world. Evidence has been documented that the immune system is impressively involved in the pathogenesis of this disease, especially in causing inflammation. One of the important components of the immune system is the complement system whose increased activity has been shown in inflammatory diseases and consequently damage caused by the activity of its components. In the present study, serum levels of C3 and C4 factors as well as the activity level of complement system in the classical pathway were measured by CH50 test in patients with SARS-CoV-2. Participants in the study consisted of 53 hospitalized patients whose real-time PCR test was positive for SARS-CoV-2. The mean age of these patients was 42.06 ± 18.7 years, including 40% women and 60% men. The most common symptoms in these patients were cough (70%), fever (59%), dyspnea (53%) and chills (53%), respectively. Analysis of biochemical and hematological test results revealed that 26 (49%) patients had lymphopenia, 34 (64%) patients were positive for C-reactive protein (CRP) and 26 (49%) patients had ESR and LDH levels significantly higher than normal. In addition, 27 patients (51%) had vitamin D deficiency. The mean CH50 activity level in COVID-19 patients was significantly reduced compared to healthy individuals (84.9 versus 169.9 U/ml, p = < 0.0001). Comparison of the mean CH50 activity levels between different subgroups of patients indicated that COVID-19 patients with decreased peripheral blood lymphocyte count and positive CRP had a significant increase in activity compared to the other groups ( p = 0.0002). The serum levels of C3 and C4 factors had no significant change between patients and healthy individuals. Conclusion: The activity level of complement system in the classical pathway decreases in COVID-19 patients compared to healthy individuals, due to increased activity of complement system factors in these patients.

show abstract

“…Importantly, none of these patients had a history of systemic autoimmune rheumatic disease. Similarly, rheumatoid factor, ANA, and ANCA were detected in another cohort of severe and critically ill COVID-19 patients (Mobini et al, 2020). These clinical findings suggest that SARS-CoV-2 infection may induce autoimmune activation.…”

Section: Antibody-mediated Pathogenesis In Covid-19 Patientsmentioning

confidence: 55%

<strong>Antibody Response and Therapy in COVID-19 Patients: Significance in Vaccine Development</strong>

Lu¹,

Zhang²,

Zhan³

et al. 2020

Preprint

View full text Add to dashboard Cite

The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people and caused tremendous morbidity and mortality worldwide. Effective treatment for coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 infection is lacking and different therapeutic strategies are under testing. Host humoral and cellular immunity to SARS-CoV-2 infection is a critical determinant for patients’ outcome. SARS-CoV-2 infection results in seroconversion and production of anti-SARS-CoV-2 antibodies. The antibodies may suppress viral replication through neutralization but also might also participate in COVID-19 pathogenesis through a process termed antibody-dependent enhancement. Rapid progress has been made in the research of antibody response and therapy in COVID-19 patients including characterization of the clinical features of antibody responses in different populations infected by SARS-CoV-2, treatment of COVID-19 patients with convalescent plasma and intravenous immunoglobin products, isolation and characterization of a large panel of monoclonal neutralizing antibodies, as well as preliminary clinical results from several COVID-19 vaccine candidates. In this review, we summarize the recent progress and discuss the implications of these findings in vaccine development.

show abstract

Vasculitis-Associated Auto-antibodies and Complement Levels in patients with COVID-19 Infection

Cited by 6 publications

References 19 publications

Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?

Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?

Patients with Covid 19 have significantly reduced CH50 activity

<strong>Antibody Response and Therapy in COVID-19 Patients: Significance in Vaccine Development</strong>

Contact Info

Product

Resources

About